News

Live Streaming of Demystifying Pyrazinamide Workshop–September 5 & 6

On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS Research, and the Stop TB Partnership Working Group on New Drugs. There will be live streaming available. The links for each day of the workshop are:

Wednesday, Sept 5: http://webcast.jhu.edu/mediasite/Viewer/?peid=3b4755fe8625440a8ea96b43b353a2551d

Thursday, Sept 6: http://webcast.jhu.edu/mediasite/Viewer/?peid=688e4fd4f60140a4955c208894e334d71d

CLICK HERE FOR FULL AGENDA

Purpose: The workshop aims to highlight ongoing PZA research, provide overview of current knowledge, identify knowledge gaps, identify potential collaborations, establish priorities and strategies to achieve objectives, and perhaps identify more research funding.

The focus of the workshop is intended to improve the use of PZA in any way that makes sense in the context of combo therapy. As a single drug for treatment use, PZA is not relevant. But how it can be improved within combinations is the ultimate aim, including improved and rapid susceptibility testing.

Note: Presentations will be archived and made available to the public on a meeting page that can be accessed from the “Meetings” tab on the main menu at www.newtbdrugs.org shortly after the conclusion of the workshop.

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...